Sen Ma1,2, Christopher T Nguyen3, Fei Han4, Nan Wang1,2, Zixin Deng2, Nader Binesh5, Franklin G Moser6, Anthony G Christodoulou2, Debiao Li1,2. 1. Department of Bioengineering, University of California, Los Angeles, Los Angeles, California. 2. Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California. 3. Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts. 4. Siemens Healthcare, Los Angeles, California. 5. S. Mark Taper Foundation Imaging Center, Cedars-Sinai Medical Center, Los Angeles, California. 6. Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
PURPOSE: To develop a simultaneous T1 , T2 , and ADC mapping method that provides co-registered, distortion-free images and enables multiparametric quantification of 3D brain coverage in a clinically feasible scan time with the MR Multitasking framework. METHODS: The T1 /T2 /diffusion weighting was generated by a series of T2 preparations and diffusion preparations. The underlying multidimensional image containing 3 spatial dimensions, 1 T1 weighting dimension, 1 T2 -preparation duration dimension, 1 b-value dimension, and 1 diffusion direction dimension was modeled as a 5-way low-rank tensor. A separate real-time low-rank model incorporating time-resolved phase correction was also used to compensate for both inter-shot and intra-shot phase inconsistency induced by physiological motion. The proposed method was validated on both phantom and 16 healthy subjects. The quantification of T1 /T2 /ADC was evaluated for each case. Three post-surgery brain tumor patients were scanned for demonstration of clinical feasibility. RESULTS: Multitasking T1 /T2 /ADC maps were perfectly co-registered and free from image distortion. Phantom studies showed substantial quantitative agreement ( R 2 = 0.999 ) with reference protocols for T1 /T2 /ADC. In vivo studies showed nonsignificant T1 (P = .248), T2 (P = .97), ADC (P = .328) differences among the frontal, parietal, and occipital regions. Although Multitasking showed significant differences of T1 (P = .03), T2 (P < .001), and ADC (P = .001) biases against the references, the mean bias estimates were small (ΔT1 % < 5%, ΔT2 % < 7%, ΔADC% < 5%), with all intraclass correlation coefficients greater than 0.82 indicating "excellent" agreement. Patient studies showed that Multitasking T1 /T2 /ADC maps were consistent with the clinical qualitative images. CONCLUSION: The Multitasking approach simultaneously quantifies T1 /T2 /ADC with substantial agreement with the references and is promising for clinical applications.
PURPOSE: To develop a simultaneous T1 , T2 , and ADC mapping method that provides co-registered, distortion-free images and enables multiparametric quantification of 3D brain coverage in a clinically feasible scan time with the MR Multitasking framework. METHODS: The T1 /T2 /diffusion weighting was generated by a series of T2 preparations and diffusion preparations. The underlying multidimensional image containing 3 spatial dimensions, 1 T1 weighting dimension, 1 T2 -preparation duration dimension, 1 b-value dimension, and 1 diffusion direction dimension was modeled as a 5-way low-rank tensor. A separate real-time low-rank model incorporating time-resolved phase correction was also used to compensate for both inter-shot and intra-shot phase inconsistency induced by physiological motion. The proposed method was validated on both phantom and 16 healthy subjects. The quantification of T1 /T2 /ADC was evaluated for each case. Three post-surgery brain tumorpatients were scanned for demonstration of clinical feasibility. RESULTS: Multitasking T1 /T2 /ADC maps were perfectly co-registered and free from image distortion. Phantom studies showed substantial quantitative agreement ( R 2 = 0.999 ) with reference protocols for T1 /T2 /ADC. In vivo studies showed nonsignificant T1 (P = .248), T2 (P = .97), ADC (P = .328) differences among the frontal, parietal, and occipital regions. Although Multitasking showed significant differences of T1 (P = .03), T2 (P < .001), and ADC (P = .001) biases against the references, the mean bias estimates were small (ΔT1 % < 5%, ΔT2 % < 7%, ΔADC% < 5%), with all intraclass correlation coefficients greater than 0.82 indicating "excellent" agreement. Patient studies showed that Multitasking T1 /T2 /ADC maps were consistent with the clinical qualitative images. CONCLUSION: The Multitasking approach simultaneously quantifies T1 /T2 /ADC with substantial agreement with the references and is promising for clinical applications.
Authors: Jelle O Barentsz; Jeffrey C Weinreb; Sadhna Verma; Harriet C Thoeny; Clare M Tempany; Faina Shtern; Anwar R Padhani; Daniel Margolis; Katarzyna J Macura; Masoom A Haider; Francois Cornud; Peter L Choyke Journal: Eur Urol Date: 2015-09-08 Impact factor: 20.096
Authors: Zhehao Hu; Anthony G Christodoulou; Nan Wang; Jaime L Shaw; Shlee S Song; Marcel M Maya; Mariko L Ishimori; Lindsy J Forbess; Jiayu Xiao; Xiaoming Bi; Fei Han; Debiao Li; Zhaoyang Fan Journal: Magn Reson Med Date: 2020-04-16 Impact factor: 4.668
Authors: Hernán Jara; Osamu Sakai; Ezequiel Farrher; Ana-Maria Oros-Peusquens; N Jon Shah; David C Alsop; Kathryn E Keenan Journal: Radiology Date: 2022-08-30 Impact factor: 29.146
Authors: Tianle Cao; Sen Ma; Nan Wang; Sara Gharabaghi; Yibin Xie; Zhaoyang Fan; Elliot Hogg; Chaowei Wu; Fei Han; Michele Tagliati; E Mark Haacke; Anthony G Christodoulou; Debiao Li Journal: Magn Reson Med Date: 2021-10-27 Impact factor: 3.737
Authors: Brendan L Eck; Scott D Flamm; Deborah H Kwon; W H Wilson Tang; Claudia Prieto Vasquez; Nicole Seiberlich Journal: Prog Nucl Magn Reson Spectrosc Date: 2020-11-06 Impact factor: 9.795
Authors: Mary Kate Manhard; Jason Stockmann; Congyu Liao; Daniel Park; Sohyun Han; Merlin Fair; Maaike van den Boomen; Jon Polimeni; Berkin Bilgic; Kawin Setsompop Journal: Magn Reson Med Date: 2021-03-25 Impact factor: 3.737
Authors: Sen Ma; Nan Wang; Zhaoyang Fan; Marwa Kaisey; Nancy L Sicotte; Anthony G Christodoulou; Debiao Li Journal: Magn Reson Med Date: 2020-10-26 Impact factor: 4.668